Latest RXRX news

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model

Business Wire · Mon, 21 Sep 2026 09:14:00 -0400

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion's RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a co.

Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference

MarketBeat · Sun, 20 Sep 2026 21:02:45 -0400

Recursion Pharmaceuticals NASDAQ: RXRX outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley's Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company's shift toward an end-to-end, AI-enabled drug discovery and development platform.

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks Investment Research · Wed, 16 Sep 2026 18:51:13 -0400

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Tue, 15 Sep 2026 13:01:49 -0400

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Zacks Investment Research · Thu, 10 Sep 2026 18:50:22 -0400

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.

2 Beaten-Down Stocks to Avoid Right Now

The Motley Fool · Tue, 08 Sep 2026 14:00:01 -0400

Teladoc's business isn't making much progress, despite expanding insurance coverage within one of its most important segments. Recursion Pharmaceuticals claims that its approach to drug development is superior, but so far, it has yet to prove that claim.

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Zacks Investment Research · Fri, 04 Sep 2026 12:37:07 -0400

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

Market information is provided for research and visualization and is not investment advice.